| Year |
Citation |
Score |
| 2024 |
Lieberman MM, Tong JH, Odukwe NU, Chavel CA, Purdon TJ, Burchett R, Gillard BM, Brackett CM, McGray AJR, Bramson JL, Brentjens RJ, Lee KP, Olejniczak SH. Endogenous CD28 drives CAR T cell responses in multiple myeloma. Biorxiv : the Preprint Server For Biology. PMID 38562904 DOI: 10.1101/2024.03.21.586084 |
0.361 |
|
| 2024 |
Holling GA, Chavel CA, Sharda AP, Lieberman MM, James CM, Lightman SM, Tong JH, Qiao G, Emmons TR, Giridharan T, Hou S, Intlekofer AM, Higashi RM, Fan TWM, Lane AN, ... ... Olejniczak SH, et al. CD8+ T cell metabolic flexibility elicited by CD28-ARS2 axis-driven alternative splicing of PKM supports antitumor immunity. Cellular & Molecular Immunology. PMID 38233562 DOI: 10.1038/s41423-024-01124-2 |
0.318 |
|
| 2023 |
Dong B, Obermajer N, Tsuji T, Matsuzaki J, Bonura C, Withers H, Long M, Chavel C, Olejniczak SH, Minderman H, Edwards RP, Storkus WJ, Romero P, Kalinski P. NK Receptors Replace CD28 As the Dominant Source of Signal 2 for Cognate Recognition of Cancer Cells by TAA-specific Effector CD8 T Cells. Research Square. PMID 37886562 DOI: 10.21203/rs.3.rs-3399211/v1 |
0.332 |
|
| 2020 |
Utley A, Chavel C, Lightman S, Holling GA, Cooper J, Peng P, Liu W, Barwick BG, Gavile CM, Maguire O, Murray-Dupuis M, Rozanski C, Jordan MS, Kambayashi T, Olejniczak SH, et al. CD28 Regulates Metabolic Fitness for Long-Lived Plasma Cell Survival. Cell Reports. 31: 107815. PMID 32579940 DOI: 10.1016/J.Celrep.2020.107815 |
0.41 |
|
| 2020 |
Elahi S, Holling GA, Stablewski AB, Olejniczak SH. Improved hematopoietic differentiation of mouse embryonic stem cells through manipulation of the RNA binding protein ARS2. Stem Cell Research. 43: 101710. PMID 31986485 DOI: 10.1016/J.Scr.2020.101710 |
0.381 |
|
| 2018 |
Elahi S, Egan SM, Holling GA, Kandefer RL, Nemeth MJ, Olejniczak SH. The RNA binding protein Ars2 supports hematopoiesis at multiple levels. Experimental Hematology. PMID 29775646 DOI: 10.1016/J.Exphem.2018.05.001 |
0.401 |
|
| 2016 |
Olejniczak SH, La Rocca G, Radler MR, Egan SM, Xiang Q, Garippa R, Thompson CB. Coordinated regulation of cap-dependent translation and microRNA function by convergent signaling pathways. Molecular and Cellular Biology. PMID 27354062 DOI: 10.1128/Mcb.01011-15 |
0.361 |
|
| 2015 |
La Rocca G, Olejniczak SH, González AJ, Briskin D, Vidigal JA, Spraggon L, DeMatteo RG, Radler MR, Lindsten T, Ventura A, Tuschl T, Leslie CS, Thompson CB. In vivo, Argonaute-bound microRNAs exist predominantly in a reservoir of low molecular weight complexes not associated with mRNA. Proceedings of the National Academy of Sciences of the United States of America. 112: 767-72. PMID 25568082 DOI: 10.1073/Pnas.1424217112 |
0.353 |
|
| 2013 |
Olejniczak SH, La Rocca G, Gruber JJ, Thompson CB. Long-lived microRNA-Argonaute complexes in quiescent cells can be activated to regulate mitogenic responses. Proceedings of the National Academy of Sciences of the United States of America. 110: 157-62. PMID 23248281 DOI: 10.1073/Pnas.1219958110 |
0.344 |
|
| 2012 |
Blickwedehl J, Olejniczak S, Cummings R, Sarvaiya N, Mantilla A, Chanan-Khan A, Pandita TK, Schmidt M, Thompson CB, Bangia N. The proteasome activator PA200 regulates tumor cell responsiveness to glutamine and resistance to ionizing radiation. Molecular Cancer Research : McR. 10: 937-44. PMID 22550082 DOI: 10.1158/1541-7786.Mcr-11-0493-T |
0.436 |
|
| 2012 |
Tsai PC, Hernandez-Ilizaliturri FJ, Bangia N, Olejniczak SH, Czuczman MS. Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1039-50. PMID 22228637 DOI: 10.1158/1078-0432.Ccr-11-1429 |
0.489 |
|
| 2011 |
Brem EA, Thudium K, Khubchandani S, Tsai PC, Olejniczak SH, Bhat S, Riaz W, Gu J, Iqbal A, Campagna R, Knight J, Mavis C, Hoskin P, Deeb G, Gibbs JF, et al. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. British Journal of Haematology. 153: 599-611. PMID 21492126 DOI: 10.1111/J.1365-2141.2011.08669.X |
0.561 |
|
| 2010 |
Olejniczak SH, Blickwedehl J, Belicha-Villanueva A, Bangia N, Riaz W, Mavis C, Clements JL, Gibbs J, Hernandez-Ilizaliturri FJ, Czuczman MS. Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells. Blood. 116: 5605-14. PMID 20930068 DOI: 10.1182/Blood-2009-12-259754 |
0.702 |
|
| 2010 |
Tsai P, Dvorak P, Bangia N, Olejniczak S, Czuczman MS, Hernandez-Ilizaliturri FJ. Rituximab Resistance Is Associated with Global Downregulation of CD20 and CD54 In B-Cell Lymphoma Cells: Implication of CD20 Signaling on CD54 Blood. 116: 5077-5077. DOI: 10.1182/Blood.V116.21.5077.5077 |
0.474 |
|
| 2009 |
Hernandez-Ilizaliturri FJ, Khubchandani S, Olejniczak SH, Hoskin P, Czuczman MS. Strategies to overcoming rituximab-chemotherapy resistance by targeting the autophagy pathway using bortezomib in combination with the Bcl-2 inhibitor obatoclax in non-Hodgkin's lymphomas (NHL) Journal of Clinical Oncology. 27: 8543-8543. DOI: 10.1200/Jco.2009.27.15_Suppl.8543 |
0.556 |
|
| 2008 |
Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, Knight J, Starostik P, Deans J, Hernandez-Ilizaliturri FJ. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 1561-70. PMID 18316581 DOI: 10.1158/1078-0432.Ccr-07-1254 |
0.554 |
|
| 2008 |
Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 1550-60. PMID 18316580 DOI: 10.1158/1078-0432.Ccr-07-1255 |
0.709 |
|
| 2008 |
Hernandez-Ilizaliturri FJ, Khubchandani S, Olejniczak SH, Hosking P, Gruber E, Czuczman M. The BH3-Mimetic Obatoclax (GX15-070) Posses a Dual-Mechanism of Action and Induces Both Apoptosis and Autophagy-Dependent Cell Death of B Cell Non-Hodgkin’s Lymphoma (B-NHL) Cells Blood. 112: 605-605. DOI: 10.1182/Blood.V112.11.605.605 |
0.611 |
|
| 2008 |
Khubchandani S, Mashtare T, Chisti MM, Wilding G, Olejniczak S, Czuczman MS, Hernandez-Ilizaliturri FJ. CD20 Antigen Density at Time of Presentation Is An Independent Predictor of Outcome in B-Cell Lymphoproliferative Disorders Blood. 112: 5312-5312. DOI: 10.1182/Blood.V112.11.5312.5312 |
0.48 |
|
| 2008 |
Tsai P, Bangia N, Olejniczak S, Hernandez-Ilizaliturri FJ, Czuczman M. The Acquirement of Rituximab Resistance Is Associated with a Global Downregulation of CD54 in B-Cell Lymphoma Cells: The Potential Role of Adhesion Molecules in Rituximab Anti-Tumor Activity Blood. 112: 2607-2607. DOI: 10.1182/Blood.V112.11.2607.2607 |
0.582 |
|
| 2007 |
Cruz RI, Hernandez-Ilizaliturri FJ, Olejniczak S, Deeb G, Knight J, Wallace P, Thurberg BL, Kennedy W, Czuczman MS. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leukemia & Lymphoma. 48: 2424-36. PMID 18067019 DOI: 10.1080/10428190701647879 |
0.556 |
|
| 2007 |
Tsai P, Hernandez-Ilizaliturri FJ, Olejniczak SH, Naveen B, Czuczman MS. Modulation of CD20 Expression in Rituximab-Sensitive (RSCL) and Rituximab Resistant Cell Lines (RRCL) Using IL-4 and Bryostatin-1. Blood. 110: 2619-2619. DOI: 10.1182/Blood.V110.11.2619.2619 |
0.51 |
|
| 2007 |
Gruber EA, Czuczman MS, Olejniczak SH, Knight J, Hernandez-Ilizaliturri FJ. GX15-070 and Bortezomib Induce Up-Regulation of BH3 Single Domain Pro-Apoptotic Proteins Puma and Noxa and Is Associated with Synergistic Anti-Tumor Activity in Rituximab-Sensitive, Rituximab-Resistant Cell Lines (RSCL and RRCL), and Primary Lymphoma Patient Specimens. Blood. 110: 1389-1389. DOI: 10.1182/Blood.V110.11.1389.1389 |
0.618 |
|
| 2006 |
Olejniczak SH, Stewart CC, Donohue K, Czuczman MS. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunological Investigations. 35: 93-114. PMID 16531332 DOI: 10.1080/08820130500496878 |
0.487 |
|
| 2006 |
Hernandez-Ilizaliturri FJ, Kaur H, Bhinder A, Olejniczak S, Knight J, Czuczman MS. Impaired Ca++ mobilization in rituximab-resistant cells (RRCL) is associated with changes in the structure of CD20 antigen, down-regulation of Bax/Bak pro-apoptotic proteins and up-regulation of the endoplasmic reticulum (ER) Ca++ pump protein SERCA-3 Journal of Clinical Oncology. 24: 2516-2516. DOI: 10.1200/Jco.2006.24.18_Suppl.2516 |
0.44 |
|
| 2006 |
Reddy NM, Hernandez-Ilizaliturri FJ, Olejniczak S, Knight J, Czuczman MS. Rituximab resistance and its association with changes in the internal domain of CD20 antigen and down-regulation of pro-apoptotic protein Bax and Bak in both rituximab-resistant cell lines (RRCL) and diffuse large B-cell lymphoma (DLBCL) patient (pt) samples Journal of Clinical Oncology. 24: 17509-17509. DOI: 10.1200/Jco.2006.24.18_Suppl.17509 |
0.605 |
|
| 2006 |
Olejniczak SH, Clements JL, Bangia N, Hernandez-Ilizaliturri FJ, Czuczman MS. Down-Regulation of Bax and Bak in Immuno-Chemotherapy Resistant Non-Hodgkin’s Lymphoma Cells. Blood. 108: 4758-4758. DOI: 10.1182/Blood.V108.11.4758.4758 |
0.712 |
|
| 2006 |
Hernandez-Ilizaliturri FJ, Iqbal A, Alam N, Bhat S, Olejniczak S, Knight J, Czuczman MS. Targeting BH3-Domain Anti-Apoptotic Proteins with GX15-070 Decreases DNA Synthesis, Induces Cell Death and Sensitizes Rituximab-Sensitive and Resistant Non-Hodgkin’s Lymphoma Cell Lines to the Anti-Tumor Activity of Chemotherapy Agents. Blood. 108: 2523-2523. DOI: 10.1182/Blood.V108.11.2523.2523 |
0.619 |
|
| 2006 |
Hernandez-Ilizaliturri FJ, Bhat S, Iqbal A, Olejniczak S, Knight J, Czuczman MS. Targeting BH3-Domain Anti-Apoptotic Proteins with GX15-070 Significantly Increases Rituximab-Mediated Antibody Dependent Cellular Cytotoxicity (ADCC) and Complement Mediated Cytotoxicity (CMC) Against B-Cell Lymphomas. Blood. 108: 2502-2502. DOI: 10.1182/Blood.V108.11.2502.2502 |
0.558 |
|
| 2005 |
Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Loss of Expression of the Pro-Apoptotic Bcl-2 Family Proteins Bak and Bax in Rituximab- and Chemotherapy-Resistant Non-Hodgkin’s Lymphoma Cells. Blood. 106: 4819-4819. DOI: 10.1182/Blood.V106.11.4819.4819 |
0.72 |
|
| 2005 |
Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Lack of Lipid Raft Domain Reorganization Following Ligation of CD20 Is Associated with Resistance to Rituximab-Induced Complement-Dependent Cytotoxicity. Blood. 106: 4818-4818. DOI: 10.1182/Blood.V106.11.4818.4818 |
0.704 |
|
| 2005 |
Hernandez-Ilizaliturri FJ, Olejniczak SH, Knight J, Czuczman MS. Structural Changes in the Internal Domain of CD20 Antigen Associated with the Emergence of Rituximab Resistance: Effects of Proteasome Inhibition in CD20 Structure and Rituximab Anti-Tumor Activity in Rituximab-Resistant Cell Lines (RRCL). Blood. 106: 1474-1474. DOI: 10.1182/Blood.V106.11.1474.1474 |
0.473 |
|
| 2004 |
Olejniczak SH, Hernandez FJ, Czuczman MS. Acquirement of Rituximab Resistance Is Associated with the Development of Chemotherapy Resistance in B-Cell Lymphoma Cells: Evidence of Shared Pathways of Resistance between Chemotherapeutic Agents and Biological Therapies. Blood. 104: 2297-2297. DOI: 10.1182/Blood.V104.11.2297.2297 |
0.664 |
|
| 2004 |
Czuczman MS, Olejniczak S, Gowda AC, Starostik P, Hernandez-Ilizaliturri FJ. Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Structural Changes in the Internal Domain of CD20 Regulated at the Post-Transcriptional Level. Blood. 104: 2280-2280. DOI: 10.1182/Blood.V104.11.2280.2280 |
0.485 |
|
| Show low-probability matches. |